Industry news that matters to you.  Learn more

Archives for May 2015

Personal Genome Diagnostics Study Highlights Limitations of Tumor-only Sequencing for Cancer

Personal Genome Diagnostics, Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, recently announced the publication of a landmark study showing that many of the genetic alterations identified using tumor-only sequencing are not actually associated with the cancer, but instead reflect inherited germline mutations already present in the normal cells of the individual. The study is in the April 15 edition of Science Translational Medicine and was conducted by PGDx scientists working in collaboration with company co-founders Dr. Victor Velculescu and Dr. Luis Diaz, Jr. and their colleagues at Johns Hopkins University.

PDI, Inc. Subsidiary Interpace Diagnostics Sets New Precedent with Launch of ThyraMIR, First and Only MicroRNA Gene Expression Classifier for Thyroid Nodule Identification

PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, recently announced the launch of ThyraMIRâ„¢, the first and only microRNA (miRNA) gene expression classifier for identification of indeterminate benign and malignant thyroid nodules.

Ventana Medical Systems, Inc. and Astellas Pharma Join Forces to Leverage Novel Companion Diagnostic Tests for Targeted Cancer Treatments

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, recently announced it has entered into master collaboration agreement with Astellas Pharma Inc., an R&D-driven global pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.